Abstract 62P
Background
Cervical intraepithelial neoplasia (CIN) is regarded as a precancerous condition of the cervix. The tumor microenvironment contains a large number of immune cells, in particular, tumor-associated neutrophils (Nph), as well as pro-inflammatory cytokines, including IL6, which causes chronic inflammation and immunosuppression. The role of IL6 in the onset and progression of CIN has been shown (Chen J, Wang L, 2022). Regulation of cytokine expression occurs at the transcriptional level, in the promoter region of the gene. For IL6, a single nucleotide polymorphism (SNP) with a substitution at position -174G→C has been described that is associated with the risk of breast cancer. IL6 polymorphism (rs2069837) is significantly associated with an increased risk of cervical cancer (Das AP, et al, 2022). However, there is no data on the involvement of SNP IL6 C-174G (rs1800795) in the occurrence and development of CIN. The aim of the study was to evaluate the role of IL6 (C-174G) polymorphism in the development of CIN.
Methods
The study included 60 patients diagnosed with high-grade squamous intraepithelial lesions (CIN II, CIN III and cancer in situ) and 30 somatically healthy women (control). The study was conducted in accordance with the requirements of the ethics commission of UlSU. The level of IL6 was determined in Nph lysate by ELISA method (Vector-Best, Russia). The presence of SNP IL6 C-174G was assessed by polymerase chain reaction with restriction enzyme analysis using RsaI endonuclease (SibEnzyme, Russia). Electrophoresis was carried out in 1.5% agarose gel. Statistical processing was carried out using Statistica 13.
Results
It was found that the -174G* allele is more common in the group with lesions of the cervix (75.7%) than in the control (53.3%). The risk of developing CIN increased with an increase in the level of IL6 in Nph with CIN (9.69 (6.89-10.85) vs 1.33 (0.78-2.25), p=0.015) and the presence of the -174G allele * (OR=0.411, 95% CI 0.220-0.768, p=0.005) (χ2=23.4, p=0.001).Simultaneous assessment of the level of IL6 in Nph and SNP IL6 C-174G allows predicting the development of CIN with sensitivity (0.769) and specificity (0.897).
Conclusions
The presence of IL6 polymorphism (C-174G) and an elevated level of IL6 in Nph indicate the possibility of CIN.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
Presenter: Lisa Wozelka-Oltjan
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Effect of sequential antitumoral treatment with immune checkpoint blockade and tyrosine kinase inhibitors in hepatocellular carcinoma
Presenter: Vincenza Ciaramella
Session: Cocktail & Poster Display session
Resources:
Abstract
127P - Novel bone-targeting of activatable sirolimus for targeted therapy of bone-resident cancers
Presenter: Alistare Sadra
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Network medicine approach identifies small molecule drugs as immune checkpoint inhibitors repurposable for rectal cancer
Presenter: Faheem Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - Repurposing existing therapies for adrenal cancer: Unlocking new possibilities
Presenter: Anupama Samantasinghar
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Restoration of the mutant p53 protein upon treatment with small molecule modulators
Presenter: Elvina Gilyazova
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Trop 2 and its overexpression in metastatic colorectal cancer patients (mCRCp): Biological, clinical and therapeutic implications
Presenter: Andrea Mancuso Petricca
Session: Cocktail & Poster Display session
Resources:
Abstract
132P - Novel small molecule modulators for activation of mutant tumor suppressor p53
Presenter: Damir Davletshin
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Cytotoxic efficacy of artificial vesicles obtained from CAR-T cells by ultrasonication
Presenter: Ekaterina Zmievskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract